Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001415889-25-001083
Filing Date
2025-01-08
Accepted
2025-01-08 14:10:39
Documents
1
Period of Report
2025-01-08

Document Format Files

Seq Description Document Type Size
1 form4-01082025_070134.html 4  
1 form4-01082025_070134.xml 4 9669
  Complete submission text file 0001415889-25-001083.txt   11174
Mailing Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-779-3100
Poseida Therapeutics, Inc. (Issuer) CIK: 0001661460 (see all company filings)

EIN.: 472846548 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O POSEIDA THERAPEUTICS 9390 TOWNE CENTRE DRIVE, SUITE 200 SAN DIEGO CA 92121
Business Address
Rizvi Syed Ali-aamir (Reporting) CIK: 0001897621 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39376 | Film No.: 25517893